Corporate Member Update: Merck- Keytruda® (pembrolizumab): Updated Indication

Merck would like to inform you that the FDA has approved KEYTRUDA® (pembrolizumab) Injection 100 mg, as a single agent, for the treatment of patients with advanced endometrial carcinoma that is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.

Information on FDA-approved tests used for patient selection is available at http://www.fda.gov/CompanionDiagnostics. FDA=Food and Drug Administration.

For more information, click here to read the rest of the press release.